
China’s National Medical Products Administration (NMPA) has approved Takeda’s Entyvio (vedolizumab) for the treatment of adult patients with ulcerative colitis …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

